1.Chinese expert consensus on blood support mode and blood transfusion strategies for emergency treatment of severe trauma patients (version 2024)
Yao LU ; Yang LI ; Leiying ZHANG ; Hao TANG ; Huidan JING ; Yaoli WANG ; Xiangzhi JIA ; Li BA ; Maohong BIAN ; Dan CAI ; Hui CAI ; Xiaohong CAI ; Zhanshan ZHA ; Bingyu CHEN ; Daqing CHEN ; Feng CHEN ; Guoan CHEN ; Haiming CHEN ; Jing CHEN ; Min CHEN ; Qing CHEN ; Shu CHEN ; Xi CHEN ; Jinfeng CHENG ; Xiaoling CHU ; Hongwang CUI ; Xin CUI ; Zhen DA ; Ying DAI ; Surong DENG ; Weiqun DONG ; Weimin FAN ; Ke FENG ; Danhui FU ; Yongshui FU ; Qi FU ; Xuemei FU ; Jia GAN ; Xinyu GAN ; Wei GAO ; Huaizheng GONG ; Rong GUI ; Geng GUO ; Ning HAN ; Yiwen HAO ; Wubing HE ; Qiang HONG ; Ruiqin HOU ; Wei HOU ; Jie HU ; Peiyang HU ; Xi HU ; Xiaoyu HU ; Guangbin HUANG ; Jie HUANG ; Xiangyan HUANG ; Yuanshuai HUANG ; Shouyong HUN ; Xuebing JIANG ; Ping JIN ; Dong LAI ; Aiping LE ; Hongmei LI ; Bijuan LI ; Cuiying LI ; Daihong LI ; Haihong LI ; He LI ; Hui LI ; Jianping LI ; Ning LI ; Xiying LI ; Xiangmin LI ; Xiaofei LI ; Xiaojuan LI ; Zhiqiang LI ; Zhongjun LI ; Zunyan LI ; Huaqin LIANG ; Xiaohua LIANG ; Dongfa LIAO ; Qun LIAO ; Yan LIAO ; Jiajin LIN ; Chunxia LIU ; Fenghua LIU ; Peixian LIU ; Tiemei LIU ; Xiaoxin LIU ; Zhiwei LIU ; Zhongdi LIU ; Hua LU ; Jianfeng LUAN ; Jianjun LUO ; Qun LUO ; Dingfeng LYU ; Qi LYU ; Xianping LYU ; Aijun MA ; Liqiang MA ; Shuxuan MA ; Xainjun MA ; Xiaogang MA ; Xiaoli MA ; Guoqing MAO ; Shijie MU ; Shaolin NIE ; Shujuan OUYANG ; Xilin OUYANG ; Chunqiu PAN ; Jian PAN ; Xiaohua PAN ; Lei PENG ; Tao PENG ; Baohua QIAN ; Shu QIAO ; Li QIN ; Ying REN ; Zhaoqi REN ; Ruiming RONG ; Changshan SU ; Mingwei SUN ; Wenwu SUN ; Zhenwei SUN ; Haiping TANG ; Xiaofeng TANG ; Changjiu TANG ; Cuihua TAO ; Zhibin TIAN ; Juan WANG ; Baoyan WANG ; Chunyan WANG ; Gefei WANG ; Haiyan WANG ; Hongjie WANG ; Peng WANG ; Pengli WANG ; Qiushi WANG ; Xiaoning WANG ; Xinhua WANG ; Xuefeng WANG ; Yong WANG ; Yongjun WANG ; Yuanjie WANG ; Zhihua WANG ; Shaojun WEI ; Yaming WEI ; Jianbo WEN ; Jun WEN ; Jiang WU ; Jufeng WU ; Aijun XIA ; Fei XIA ; Rong XIA ; Jue XIE ; Yanchao XING ; Yan XIONG ; Feng XU ; Yongzhu XU ; Yongan XU ; Yonghe YAN ; Beizhan YAN ; Jiang YANG ; Jiangcun YANG ; Jun YANG ; Xinwen YANG ; Yongyi YANG ; Chunyan YAO ; Mingliang YE ; Changlin YIN ; Ming YIN ; Wen YIN ; Lianling YU ; Shuhong YU ; Zebo YU ; Yigang YU ; Anyong YU ; Hong YUAN ; Yi YUAN ; Chan ZHANG ; Jinjun ZHANG ; Jun ZHANG ; Kai ZHANG ; Leibing ZHANG ; Quan ZHANG ; Rongjiang ZHANG ; Sanming ZHANG ; Shengji ZHANG ; Shuo ZHANG ; Wei ZHANG ; Weidong ZHANG ; Xi ZHANG ; Xingwen ZHANG ; Guixi ZHANG ; Xiaojun ZHANG ; Guoqing ZHAO ; Jianpeng ZHAO ; Shuming ZHAO ; Beibei ZHENG ; Shangen ZHENG ; Huayou ZHOU ; Jicheng ZHOU ; Lihong ZHOU ; Mou ZHOU ; Xiaoyu ZHOU ; Xuelian ZHOU ; Yuan ZHOU ; Zheng ZHOU ; Zuhuang ZHOU ; Haiyan ZHU ; Peiyuan ZHU ; Changju ZHU ; Lili ZHU ; Zhengguo WANG ; Jianxin JIANG ; Deqing WANG ; Jiongcai LAN ; Quanli WANG ; Yang YU ; Lianyang ZHANG ; Aiqing WEN
Chinese Journal of Trauma 2024;40(10):865-881
		                        		
		                        			
		                        			Patients with severe trauma require an extremely timely treatment and transfusion plays an irreplaceable role in the emergency treatment of such patients. An increasing number of evidence-based medicinal evidences and clinical practices suggest that patients with severe traumatic bleeding benefit from early transfusion of low-titer group O whole blood or hemostatic resuscitation with red blood cells, plasma and platelet of a balanced ratio. However, the current domestic mode of blood supply cannot fully meet the requirements of timely and effective blood transfusion for emergency treatment of patients with severe trauma in clinical practice. In order to solve the key problems in blood supply and blood transfusion strategies for emergency treatment of severe trauma, Branch of Clinical Transfusion Medicine of Chinese Medical Association, Group for Trauma Emergency Care and Multiple Injuries of Trauma Branch of Chinese Medical Association, Young Scholar Group of Disaster Medicine Branch of Chinese Medical Association organized domestic experts of blood transfusion medicine and trauma treatment to jointly formulate Chinese expert consensus on blood support mode and blood transfusion strategies for emergency treatment of severe trauma patients ( version 2024). Based on the evidence-based medical evidence and Delphi method of expert consultation and voting, 10 recommendations were put forward from two aspects of blood support mode and transfusion strategies, aiming to provide a reference for transfusion resuscitation in the emergency treatment of severe trauma and further improve the success rate of treatment of patients with severe trauma.
		                        		
		                        		
		                        		
		                        	
2.Preliminary exploration on operation process for autologous ozonized blood transfusion
Jianjun WU ; Yan BAI ; Yanli BAI ; Zhanshan ZHA ; Jing CHEN ; Yahan FAN ; Jiwu GONG ; Shouyong HUN ; Hongbing LI ; Zhongjun LI ; Jiajin LIN ; Chunxia LIU ; Fenghua LIU ; Jiubo LIU ; Jingling LUO ; Xianjun MA ; Deying MENG ; Shijie MU ; Mei QIN ; Hui WANG ; Haiyan WANG ; Qiushi WANG ; Quanli WANG ; Xiaoning WANG ; Yongjun WANG ; Changsong WU ; Lin WU ; Jue XIE ; Pu XU ; Liying XU ; Mingchia YANG ; Yongtao YANG ; Yang YU ; Zebo YU ; Juan ZHANG ; Xiaoyu ZHOU ; Xuelian ZHOU ; Shuming ZHAO
Chinese Journal of Blood Transfusion 2023;36(2):95-100
		                        		
		                        			
		                        			Autologous ozonized blood transfusion(AOBT) is a therapy of re-transfusion of 100-200 mL of autologous blood after shaking and agitation with appropriate amount of oxygen-ozone in vitro. The oxidation of blood through the strong oxidation of ozone can enhance the non-specific immune response of the body, regulate the internal environment and promote health. This therapy has been increasingly applied in clinical practice, while no unified standard for the operation process in terms of ozone concentration, treatment frequency and treatment course had been established. This operation process of AOBT is primarily explored in order to standardize the operation process and ensure its safety and efficacy.
		                        		
		                        		
		                        		
		                        	
3.Poor prognostic factors in human papillomavirus-positive head and neck cancer: who might not be candidates for de-escalation treatment?
Shin Hye YOO ; Chan Young OCK ; Bhumsuk KEAM ; Sung Joon PARK ; Tae Min KIM ; Jin Ho KIM ; Yoon Kyung JEON ; Eun Jae CHUNG ; Seong Keun KWON ; J Hun HAH ; Tack Kyun KWON ; Kyeong Chun JUNG ; Dong Wan KIM ; Hong Gyun WU ; Myung Whun SUNG ; Dae Seog HEO
The Korean Journal of Internal Medicine 2019;34(6):1313-1323
		                        		
		                        			 BACKGROUND/AIMS:
		                        			Since patients with human papillomavirus (HPV)-associated head and neck squamous cell carcinoma (HNSCC) have favorable outcomes after treatment, treatment de-escalation for these patients is being actively investigated. However, not all HPV-positive HNSCCs are curable, and some patients have a poor prognosis. The purpose of this study was to identify poor prognostic factors in patients with HPV-positive HNSCC.
		                        		
		                        			METHODS:
		                        			Patients who received a diagnosis of HNSCC and tested positive for HPV from 2000 to 2015 at a single hospital site (n = 152) were included in this retrospective analysis. HPV typing was conducted using the HPV DNA chip assay or liquid bead microarray system. Expression of p16 in the tumors was assessed by immunohistochemistry. To determine candidate factors associated with overall survival (OS), univariate and multivariable Cox regression analyses were performed.
		                        		
		                        			RESULTS:
		                        			A total of 152 patients with HPV-positive HNSCC were included in this study; 82.2% were male, 43.4% were current or former smokers, and 84.2% had oropharyngeal cancer. By univariate analysis, old age, performance status ≥ 1, non-oropharyngeal location, advanced T classification (T3–4), and HPV genotype 18 were significantly associated with poor OS. By multivariable analysis, performance status ≥ 1 and non-oropharyngeal location were independently associated with shorter OS (hazard ratio [HR], 4.36, p = 0.015; HR, 11.83, p = 0.002, respectively). Furthermore, HPV genotype 18 positivity was also an independent poor prognostic factor of OS (HR, 10.87, p < 0.001).
		                        		
		                        			CONCLUSIONS
		                        			Non-oropharyngeal cancer, poor performance status, and HPV genotype 18 were independent poor prognostic factors in patients with HPV-positive HNSCC. Patients with these risk factors might not be candidates for de-escalation treatment. 
		                        		
		                        		
		                        		
		                        	
4.Comparison of wound healing effects between Oncorhynchus keta-derived polydeoxyribonucleotide (PDRN) and Oncorhynchus mykiss-derived PDRN.
Jong Hun LEE ; Jin Woo HAN ; Jin Hwan BYUN ; Won Mi LEE ; Min Ho KIM ; Wen Hao WU
Archives of Craniofacial Surgery 2018;19(1):20-34
		                        		
		                        			
		                        			BACKGROUND: Polydeoxyribonucleotide (PDRN) influencing cellular growth and differentiation is recognized to promote wound healing by stimulating tissue repair. Although PDRN can be extracted from human placentas, PDRN medications have recently been extracted from the semen of trout (Oncorhynchus mykiss) and salmon (Oncorhynchus keta). The present study was designed to evaluate the wound healing effects of O. keta-derived PDRN for injection (Rejuvenex) and PDRN cream (Rejuvenex Cream) in comparison with those of O. mykiss-derived PDRN injection (Placentex). METHODS: Full-thickness skin defects were made on the back of mice (n=60). The mice were divided into the following four groups according to the dressing used for the wounds: O. mykiss-derived PDRN injection group, O. keta-derived PDRN injection group, O. keta-derived PDRN cream group, and normal saline soaked dressing group (control group). We analyzed the gross findings, wound sizes, histological findings, immunohistochemistry and enzyme-linked immunosorbent assays for the groups immediately after the treatment, and again after 4, 7, and 10 days of treatment. RESULTS: The wound healing effects were the greatest in the O. keta-derived PDRN injection and O. mykiss-derived PDRN injection groups, which showed similar scores, followed by the O. keta-derived cream and normal saline soaked dressing groups. CONCLUSION: The injection of PDRN extracted from O. keta was found to be as effective at healing full-thickness skin defects as the O. mykiss-derived PDRN injection, which is currently used in the clinic. Moreover, the O. keta-derived PDRN injection was also found to reduce the time required for wound healing.
		                        		
		                        		
		                        		
		                        			Animals
		                        			;
		                        		
		                        			Bandages
		                        			;
		                        		
		                        			Enzyme-Linked Immunosorbent Assay
		                        			;
		                        		
		                        			Humans
		                        			;
		                        		
		                        			Immunohistochemistry
		                        			;
		                        		
		                        			Mice
		                        			;
		                        		
		                        			Oncorhynchus*
		                        			;
		                        		
		                        			Placenta
		                        			;
		                        		
		                        			Salmon
		                        			;
		                        		
		                        			Semen
		                        			;
		                        		
		                        			Skin
		                        			;
		                        		
		                        			Trout
		                        			;
		                        		
		                        			Wound Healing*
		                        			;
		                        		
		                        			Wounds and Injuries*
		                        			
		                        		
		                        	
5.Comparison of the Clinical Outcomes of Patients with Squamous Cell Carcinoma of the Tonsil Receiving Postoperative Ipsilateral Versus Bilateral Neck Radiotherapy: A Propensity Score Matching Analysis (KROG 11-07).
Youngkyong KIM ; Kwan Ho CHO ; Sung Ho MOON ; Chang Geol LEE ; Ki Chang KEUM ; Sang wook LEE ; Yong Chan AHN ; Dongryul OH ; Yeon Sil KIM ; Yong Kyun WON ; Hong Gyun WU ; J Hun HAH ; Young Taek OH
Cancer Research and Treatment 2017;49(4):1097-1105
		                        		
		                        			
		                        			PURPOSE: The impact of postoperative ipsilateral neck radiotherapy (INRT) versus bilateral neck radiotherapy (BNRT) on the clinical outcomes of patients with tonsillar squamous cell carcinoma was analyzed retrospectively. MATERIALS AND METHODS: Between October 2001 and June 2012, 241 patients with T1-2 and N0-N2b tonsillar carcinoma from 16 institutes underwent postoperative INRT (n=84) or BNRT (n=157) following a tonsillectomy. Seventy patients were identified from each group by propensity score matching and compared in terms of the overall survival (OS), disease-free survival (DFS), locoregional relapse-free survival (LRRFS), and distant metastasis-free survival (DMFS) rates calculated using the Kaplan-Meier method with a log-rank test. RESULTS: The median follow-up was 55 months (range, 3 to 133 months). The survival outcomes in the INRT and BNRT groups were similar: 5-year OS (92.8% vs. 94.0%, p=0.985), DFS (80.5% vs. 94.2%. p=0.085), LRRFS (88.1% vs. 97.1%, p=0.083), and DMFS (92.7% vs. 97.0%, p=0.370). Subgroup analysis revealed no contralateral neck recurrence in 61 patients with T1-2N0-2a regardless of the treatment groups. For 79 patients with N2b, contralateral neck recurrence was more common in the INRT group than in the BNRT group (7.9% vs. 0.0%), but the difference was not significant (p=0.107). The overall grade ≥ 2 toxicities were lower in the INRT group: acute (45.7% vs. 74.3%, p=0.001) and late (4.3% vs. 31.4%, p < 0.001), respectively. CONCLUSION: INRT is an attractive strategy for patients with T1-2N0-2a tonsillar carcinoma compared to BNRT. For patients with N2b, there was a small risk of contralateral neck recurrence when treated with INRT, but its impact on the OS was limited with successful salvage treatment.
		                        		
		                        		
		                        		
		                        			Academies and Institutes
		                        			;
		                        		
		                        			Carcinoma, Squamous Cell*
		                        			;
		                        		
		                        			Disease-Free Survival
		                        			;
		                        		
		                        			Epithelial Cells*
		                        			;
		                        		
		                        			Follow-Up Studies
		                        			;
		                        		
		                        			Humans
		                        			;
		                        		
		                        			Methods
		                        			;
		                        		
		                        			Neck*
		                        			;
		                        		
		                        			Palatine Tonsil*
		                        			;
		                        		
		                        			Propensity Score*
		                        			;
		                        		
		                        			Radiotherapy*
		                        			;
		                        		
		                        			Radiotherapy, Adjuvant
		                        			;
		                        		
		                        			Recurrence
		                        			;
		                        		
		                        			Retrospective Studies
		                        			;
		                        		
		                        			Salvage Therapy
		                        			;
		                        		
		                        			Tonsillar Neoplasms
		                        			;
		                        		
		                        			Tonsillectomy
		                        			
		                        		
		                        	
6.Prohibitin2 expression and its relation with astrocyte proliferation in rats after traumatic brain injury
Ting XU ; Hun WU ; Xingxing GU ; Long MA ; Yi WANG ; Yangyou YU
Chinese Journal of Neuromedicine 2017;16(7):671-675
		                        		
		                        			
		                        			Objective To research the prohibitin2 (PHB2) expression and cellular localization in the rat brain cortex after traumatic brain injury (TBI),and explore its relationship with astrocyte proliferation and neuron apoptosis.Methods TBI rat models were established by knife injurying the brain.Western blotting was used to detect the PHB2 expression variation trend in the brain cortex.Immunohistochemical method was used to detect the distribution of PHB2 in damaged cerebral cortex,and immunofluorescence was applied to research the PHB2 expression changes and cellular localization in the rat brain cortex after TBI,and explore its relationship with astrocyte proliferation and neuron apoptosis.Results (1) The TBI models were established successfully;12 h after TBI,the PHB2 expression started to increase obviously,and PHB2 expression reached to its peak level 5 d after TBI.(2)The PHB2 expression in the cortex of TBI rats was significantly increased as compared with that in the sham-operated group,control group and contralateral side of TBI rats.(3) PHB2 mainly located at the astrocytes and neurons of the cerebral cortex after TBI.(4) Co-localization was noted in astrocytes and cell proliferation marker PCNA,and in PHB2 and PCNA,which indicated that proliferation of astrocytes existed and PHB2 involved in the proliferation.(5) Co-localization was noted in astrocytes and cell apoptosis marker A-caspase-3,and in PHB2 and A-caspase-3,which indicated that TBI induced cell apoptosis,and PHB2 involved in the apoptosis.Conclusion PHB2 has a high expression in the cerebral cortex of rats after TBI,and these changes are related to astrocyte proliferation and neuronal apoptosis.
		                        		
		                        		
		                        		
		                        	
7.Induction chemotherapy in head and neck squamous cell carcinoma of the paranasal sinus and nasal cavity: a role in organ preservation.
Chan Young OCK ; Bhumsuk KEAM ; Tae Min KIM ; Doo Hee HAN ; Tae Bin WON ; Se Hoon LEE ; J Hun HAH ; Tack Kyun KWON ; Dong Wan KIM ; Dong Young KIM ; Chae Seo RHEE ; Hong Gyun WU ; Myung Whun SUNG ; Dae Seog HEO
The Korean Journal of Internal Medicine 2016;31(3):570-578
		                        		
		                        			
		                        			BACKGROUND/AIMS: The role of induction chemotherapy (IC) for eyeball preservation has not been established in head and neck squamous cell carcinoma (HNSCC) of the paranasal sinus and nasal cavity (PNSNC). Periorbital involvement frequently leads to eyeball exenteration with a margin of safety. We evaluated the treatment outcomes, including survival and eyeball preservation, of patients who received IC for HNSCC of the PNSNC. METHODS: We reviewed 21 patients diagnosed with HNSCC of the PNSNC who were treated with IC. We analyzed response, eyeball preservation rate, and overall survival. RESULTS: Tumors were located in the paranasal sinus (n = 14) or nasal cavity (n = 7). Most patients had stage T4a (n = 10) or T4b (n = 7) disease. More than half of the patients received a chemotherapy regimen of docetaxel, fluorouracil, and cisplatin (n = 11). Thirteen patients (61.9%) achieved a partial response after IC and 15 patients (71.4%) achieved T down-staging. Among 17 patients with stage T4 disease, which confers a high risk of orbital exenteration, 14 (82.4%) achieved preservation of the involved eye. The 3-year overall survival (OS) rate of patients who achieved a partial response to IC was 84.6%. The 3-year OS rate of patients with stable disease or disease progression after IC was 25.0% (p = 0.038). CONCLUSIONS: IC could be considered for down-staging patients with advanced T-stage disease. It could also be a reasonable option for eyeball preservation in locally advanced HNSCC of the PNSNC.
		                        		
		                        		
		                        		
		                        			Carcinoma, Squamous Cell*
		                        			;
		                        		
		                        			Cisplatin
		                        			;
		                        		
		                        			Disease Progression
		                        			;
		                        		
		                        			Drug Therapy
		                        			;
		                        		
		                        			Fluorouracil
		                        			;
		                        		
		                        			Head and Neck Neoplasms
		                        			;
		                        		
		                        			Head*
		                        			;
		                        		
		                        			Humans
		                        			;
		                        		
		                        			Induction Chemotherapy*
		                        			;
		                        		
		                        			Nasal Cavity*
		                        			;
		                        		
		                        			Neck*
		                        			;
		                        		
		                        			Orbit
		                        			;
		                        		
		                        			Orbit Evisceration
		                        			;
		                        		
		                        			Organ Preservation*
		                        			;
		                        		
		                        			Paranasal Sinuses
		                        			
		                        		
		                        	
8.The Role of Neoadjuvant Chemotherapy in the Treatment of Nasopharyngeal Carcinoma: A Multi-institutional Retrospective Study (KROG 11-06) Using Propensity Score Matching Analysis.
Jin Ho SONG ; Hong Gyun WU ; Bhum Suk KEAM ; Jeong Hun HAH ; Yong Chan AHN ; Dongryul OH ; Jae Myoung NOH ; Hyo Jung PARK ; Chang Geol LEE ; Ki Chang KEUM ; Jihye CHA ; Kwan Ho CHO ; Sung Ho MOON ; Ji Yoon KIM ; Woong Ki CHUNG ; Young Taek OH ; Won Taek KIM ; Moon June CHO ; Chul Seung KAY ; Yeon Sil KIM
Cancer Research and Treatment 2016;48(3):917-927
		                        		
		                        			
		                        			PURPOSE: We compared the treatment results and toxicity in nasopharyngeal carcinoma (NPC) patients treated with concurrent chemotherapy (CCRT) alone (the CRT arm) or neoadjuvant chemotherapy followed by CCRT (the NCT arm). MATERIALS AND METHODS: A multi-institutional retrospective study was conducted to review NPC patterns of care and treatment outcome. Data of 568 NPC patients treated by CCRT alone or by neoadjuvant chemotherapy followed by CCRT were collected from 15 institutions. Patients in both treatment arms were matched using the propensity score matching method, and the clinical outcomes were analyzed. RESULTS: After matching, 300 patients (150 patients in each group) were selected for analysis. Higher 5-year locoregional failure-free survival was observed in the CRT arm (85% vs. 72%, p=0.014). No significant differences in distant failure-free survival (DFFS), disease-free survival (DFS), and overall survival were observed between groups. In subgroup analysis, the NCT arm showed superior DFFS and DFS in stage IV patients younger than 60 years. No significant difference in compliance and toxicity was observed between groups, except the radiation therapy duration was slightly shorter in the CRT arm (50.0 days vs. 53.9 days, p=0.018). CONCLUSION: This study did not show the superiority of NCT followed by CCRT over CCRT alone. Because NCT could increase the risk of locoregional recurrences, it can only be considered in selected young patients with advanced stage IV disease. The role of NCT remains to be defined and should not be viewed as the standard of care.
		                        		
		                        		
		                        		
		                        			Arm
		                        			;
		                        		
		                        			Chemoradiotherapy
		                        			;
		                        		
		                        			Compliance
		                        			;
		                        		
		                        			Disease-Free Survival
		                        			;
		                        		
		                        			Drug Therapy*
		                        			;
		                        		
		                        			Humans
		                        			;
		                        		
		                        			Induction Chemotherapy
		                        			;
		                        		
		                        			Methods
		                        			;
		                        		
		                        			Nasopharyngeal Neoplasms
		                        			;
		                        		
		                        			Propensity Score*
		                        			;
		                        		
		                        			Radiotherapy
		                        			;
		                        		
		                        			Recurrence
		                        			;
		                        		
		                        			Republic of Korea
		                        			;
		                        		
		                        			Retrospective Studies*
		                        			;
		                        		
		                        			Standard of Care
		                        			;
		                        		
		                        			Treatment Outcome
		                        			
		                        		
		                        	
9.Distinguishing Tendon and Ligament Fibroblasts Based on ¹H Nuclear Magnetic Resonance Spectroscopy.
Hun Yeong BAN ; Ji Won SHIN ; Song I CHUN ; Yun Gyeong KANG ; Yanru WU ; Ji Eun KIM ; Eun Jin LEE ; Mi Jin KIM ; Chi Woong MUN ; Jung Woog SHIN
Tissue Engineering and Regenerative Medicine 2016;13(6):677-683
		                        		
		                        			
		                        			Tendon and ligament (T/L) have been known to be obviously different from each other in tissue level. However, due to the overlapping gene markers, distinction in cellular level has not been clearly verified yet. Recently, the use of nuclear magnetic resonance (NMR) spectroscopy has shown the potential to detect biological markers in cellular level. Therefore, in this study we applied a non-invasive technique based on NMR spectroscopy to establish biomarkers to distinguish between T/L fibroblasts. In addition the cellular morphologies and gene expression patterns were also investigated for comparison through optical microscopy and real-time polymerase chain reaction (PCR). No difference was observed from morphology and real-time PCR results, either as expected. However, we found clear differences in their metabolomic spectra using ¹H NMR spectroscopy. The calculated integral values of fatty acids (with chemical shifts at ~0.9, 1.26, 1.59, 2.05, 2.25, and 2.81 ppm), lactate (~1.33 ppm), and leucine (~2.72 ppm) were significantly different between the two types of fibroblasts. To be specific tendon group exhibited higher level of the metabolite than ligament group. In conclusion, in-cell metabolomic evaluation by NMR technique used in this study is believed to provide a promising tool in distinguishing cell types, especially T/L cells, which cannot be classified by conventional biological assays.
		                        		
		                        		
		                        		
		                        			Biological Assay
		                        			;
		                        		
		                        			Biomarkers
		                        			;
		                        		
		                        			Fatty Acids
		                        			;
		                        		
		                        			Fibroblasts*
		                        			;
		                        		
		                        			Gene Expression
		                        			;
		                        		
		                        			Genes, Overlapping
		                        			;
		                        		
		                        			Lactic Acid
		                        			;
		                        		
		                        			Leucine
		                        			;
		                        		
		                        			Ligaments*
		                        			;
		                        		
		                        			Magnetic Resonance Spectroscopy*
		                        			;
		                        		
		                        			Metabolomics
		                        			;
		                        		
		                        			Microscopy
		                        			;
		                        		
		                        			Real-Time Polymerase Chain Reaction
		                        			;
		                        		
		                        			Spectrum Analysis*
		                        			;
		                        		
		                        			Tendons*
		                        			
		                        		
		                        	
10.Long-Term Outcome of Definitive Radiotherapy for Early Glottic Cancer: Prognostic Factors and Patterns of Local Failure.
Yu Jin LIM ; Hong Gyun WU ; Tack Kyun KWON ; J Hun HAH ; Myung Whun SUNG ; Kwang Hyun KIM ; Charn Il PARK
Cancer Research and Treatment 2015;47(4):862-870
		                        		
		                        			
		                        			PURPOSE: This study evaluates the long-term results of definitive radiotherapy (RT) for early glottic cancer. Clinical and treatment factors related to local control and patterns of failure are analyzed. MATERIALS AND METHODS: We retrospectively reviewed 222 patients with T1-2N0 squamous cell carcinoma of the glottic larynx treated with definitive RT from 1981 to 2010. None of the patients received elective nodal RT or combined chemotherapy. The median total RT dose was 66 Gy. The daily fraction size was < 2.5 Gy in 69% and 2.5 Gy in 31% of patients. The RT field extended from the hyoid bone to the cricoid cartilage. RESULTS: The median age was 60 years, and 155 patients (70%) had T1 disease. The 5-year rates of local recurrence-free survival (LRFS) and ultimate LRFS with voice preservation were 87.8% and 90.3%, respectively. T2 (hazard ratio [HR], 2.30; 95% confidence interval [CI], 1.08 to 4.94) and anterior commissural involvement (HR, 3.37; 95% CI, 1.62 to 7.02) were significant prognostic factors for LRFS. In 34 patients with local recurrence, tumors recurred in the ipsilateral vocal cord in 28 patients. There were no contralateral vocal cord recurrences. Most acute complications included grade 1-2 dysphagia and/or hoarseness. There was no grade 3 or greater chronic toxicity. CONCLUSION: Definitive RT achieved a high cure rate, voice preservation, and tolerable toxicity in early glottic cancer. T2 stage and anterior commissural involvement were prognostic factors for local control. Further optimization of the RT method is needed to reduce the risk of ipsilateral tumor recurrence.
		                        		
		                        		
		                        		
		                        			Carcinoma, Squamous Cell
		                        			;
		                        		
		                        			Cricoid Cartilage
		                        			;
		                        		
		                        			Deglutition Disorders
		                        			;
		                        		
		                        			Drug Therapy
		                        			;
		                        		
		                        			Glottis
		                        			;
		                        		
		                        			Hoarseness
		                        			;
		                        		
		                        			Humans
		                        			;
		                        		
		                        			Hyoid Bone
		                        			;
		                        		
		                        			Laryngeal Neoplasms
		                        			;
		                        		
		                        			Larynx
		                        			;
		                        		
		                        			Neoplasm Recurrence, Local
		                        			;
		                        		
		                        			Radiotherapy*
		                        			;
		                        		
		                        			Recurrence
		                        			;
		                        		
		                        			Retrospective Studies
		                        			;
		                        		
		                        			Risk Factors
		                        			;
		                        		
		                        			Vocal Cords
		                        			;
		                        		
		                        			Voice
		                        			
		                        		
		                        	
            
Result Analysis
Print
Save
E-mail